Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6409
    -0.0016 (-0.25%)
     

  • OIL

    82.29
    -0.44 (-0.53%)
     

  • GOLD

    2,397.30
    -0.70 (-0.03%)
     

  • Bitcoin AUD

    100,810.48
    +4,554.45 (+4.73%)
     

  • CMC Crypto 200

    1,334.57
    +21.94 (+1.70%)
     

  • AUD/EUR

    0.6015
    -0.0016 (-0.27%)
     

  • AUD/NZD

    1.0889
    +0.0015 (+0.13%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,829.07
    -47.98 (-0.61%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,712.95
    -124.45 (-0.70%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know

Zacks Equity Research

Tilray, Inc. (TLRY) closed at $22.43 in the latest trading session, marking a +1.49% move from the prior day. This move outpaced the S&P 500's daily loss of 0.12%. At the same time, the Dow added 0.11%, and the tech-heavy Nasdaq gained 0.02%.

Prior to today's trading, shares of the company had lost 8.9% over the past month. This has lagged the Medical sector's gain of 5.24% and the S&P 500's gain of 4.42% in that time.

TLRY will be looking to display strength as it nears its next earnings release, which is expected to be November 12, 2019. In that report, analysts expect TLRY to post earnings of -$0.29 per share. This would mark a year-over-year decline of 262.5%. Meanwhile, our latest consensus estimate is calling for revenue of $50.26 million, up 400.08% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.09 per share and revenue of $172.60 million, which would represent changes of -91.23% and +300.19%, respectively, from the prior year.

ADVERTISEMENT

It is also important to note the recent changes to analyst estimates for TLRY. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 9.95% lower. TLRY currently has a Zacks Rank of #3 (Hold).

The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 56, which puts it in the top 22% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Tilray, Inc. (TLRY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.